NCT00652847

Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)

Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,140 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To compare the percent (%) change in plasma LDL-C concentration, after a six week course of treatment with ezetimibe 10 mg/day co-administered with an existing statin versus doubling of the existing statin dose

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	ezetimibe	ezetimibe 10 mg/day for a six week course of treatment.
DRUG	statins	patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase

Timeline

• Start date: 2005-05-01
• Primary completion: 2007-05-01
• Completion: 2007-05-01
• First posted: 2008-04-04
• Last updated: 2024-08-15